The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Angioneurotic Edema

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Angioneurotic Edema


Psychiatry related information on Angioneurotic Edema


High impact information on Angioneurotic Edema

  • C1 inhibitor and hereditary angioneurotic edema [7].
  • Angioedema induced by the angiotensin II blocker losartan [8].
  • Altered C1 inhibitor genes in type I hereditary angioedema [9].
  • These results suggest that an interaction between the idiotype of monoclonal immunoglobulins and antiidiotypic antibodies causes increased consumption of C1q and C1 inhibitor in patients with acquired angioedema and C1-inhibitor deficiency [10].
  • Patients with hereditary angioedema lack C-1 inhibitor, a plasma alpha 2-glycoprotein that inhibits both the proteolytic action of C1, the activated first component of the complement system, and the activity of components of the contact phase of coagulation: kallikrein, factor XIa, and factor XIIa [11].

Chemical compound and disease context of Angioneurotic Edema


Biological context of Angioneurotic Edema


Anatomical context of Angioneurotic Edema


Gene context of Angioneurotic Edema

  • Heterozygosity for C1 inhibitor (C1INH) deficiency results in hereditary angioedema [26].
  • Although Alu insertions have been implicated in other diseases, and a closely related AluY element is found as an insert in the C1 inhibitor gene in patients with hereditary angioedema, this is the first case of glycerol kinase deficiency caused by an Alu insertion [27].
  • METHODS: Patients with urticaria or angioedema triggered by NSAIDs were challenged with COX-2 inhibitors by the single-blinded, placebo-controlled oral method [28].
  • BACKGROUND: The safety of new anti-inflammatory drugs in patients intolerant to classic cyclooxygenase (COX) inhibitors with urticaria and angioedema has not been determined [28].
  • It is similar to vibratory angioedema (VA), but sufficient evidence to prove that DDU and VA are identical is not available [29].

Analytical, diagnostic and therapeutic context of Angioneurotic Edema


  1. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. Waytes, A.T., Rosen, F.S., Frank, M.M. N. Engl. J. Med. (1996) [Pubmed]
  2. Cyclosporin relieves arthralgia, causes angioedema. Isenberg, D.A., Snaith, M.L., Al-Khader, A.A., Cohen, S.L., Fisher, C., Morrow, W.J., Mowbray, J. N. Engl. J. Med. (1980) [Pubmed]
  3. Urticaria and angioedema induced by low-molecular-weight heparin. Odeh, M., Oliven, A. Lancet (1992) [Pubmed]
  4. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Joseph, K., Tholanikunnel, B.G., Kaplan, A.P. Proc. Natl. Acad. Sci. U.S.A. (2002) [Pubmed]
  5. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Schreiber, A.D., Zweiman, B., Atkins, P., Goldwein, F., Pietra, G., Atkinson, B., Abdou, N.I. Blood (1976) [Pubmed]
  6. Drosophila necrotic mutations mirror disease-associated variants of human serpins. Green, C., Brown, G., Dafforn, T.R., Reichhart, J.M., Morley, T., Lomas, D.A., Gubb, D. Development (2003) [Pubmed]
  7. C1 inhibitor and hereditary angioneurotic edema. Davis, A.E. Annu. Rev. Immunol. (1988) [Pubmed]
  8. Angioedema induced by the angiotensin II blocker losartan. Acker, C.G., Greenberg, A. N. Engl. J. Med. (1995) [Pubmed]
  9. Altered C1 inhibitor genes in type I hereditary angioedema. Stoppa-Lyonnet, D., Tosi, M., Laurent, J., Sobel, A., Lagrue, G., Meo, T. N. Engl. J. Med. (1987) [Pubmed]
  10. Acquired C1-inhibitor deficiency associated with antiidiotypic antibody to monoclonal immunoglobulins. Geha, R.S., Quinti, I., Austen, K.F., Cicardi, M., Sheffer, A., Rosen, F.S. N. Engl. J. Med. (1985) [Pubmed]
  11. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. Schapira, M., Silver, L.D., Scott, C.F., Schmaier, A.H., Prograis, L.J., Curd, J.G., Colman, R.W. N. Engl. J. Med. (1983) [Pubmed]
  12. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. Gadek, J.E., Hosea, S.W., Gelfand, J.A., Santaella, M., Wickerhauser, M., Triantaphyllopoulos, D.C., Frank, M.M. N. Engl. J. Med. (1980) [Pubmed]
  13. Androgen therapy in hereditary angioneurotic edema. Rosen, F.S., Austen, K.F. N. Engl. J. Med. (1976) [Pubmed]
  14. Epsilon aminocaproic acid for hereditary angioedema. Frank, M., Gelfand, J.A., Alling, D.W., Sherins, R.J. N. Engl. J. Med. (1977) [Pubmed]
  15. Angioneurotic edema from doxorubicin. Maldonado, J.E. N. Engl. J. Med. (1979) [Pubmed]
  16. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Caliezi, C., Wuillemin, W.A., Zeerleder, S., Redondo, M., Eisele, B., Hack, C.E. Pharmacol. Rev. (2000) [Pubmed]
  17. Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. Ariga, T., Igarashi, T., Ramesh, N., Parad, R., Cicardi, M., Davis, A.E. J. Clin. Invest. (1989) [Pubmed]
  18. Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. Cicardi, M., Igarashi, T., Kim, M.S., Frangi, D., Agostoni, A., Davis, A.E. J. Clin. Invest. (1987) [Pubmed]
  19. Efficient detection of point mutations on color-coded strands of target DNA. Verpy, E., Biasotto, M., Meo, T., Tosi, M. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  20. Clusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Stoppa-Lyonnet, D., Carter, P.E., Meo, T., Tosi, M. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  21. Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. Kramer, J., Katz, Y., Rosen, F.S., Davis, A.E., Strunk, R.C. J. Clin. Invest. (1991) [Pubmed]
  22. Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation. Donaldson, V.H., Harrison, R.A. Blood (1982) [Pubmed]
  23. Histamine inhalation challenge in recurrent uvula angioedema. Bucca, C.B., Brussino, L., Cavalot, A., Cicolin, A., Cortesina, G., Baron, P., Pagano, M., Rolla, G. J. Allergy Clin. Immunol. (2003) [Pubmed]
  24. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. van Doorn, M.B., Burggraaf, J., van Dam, T., Eerenberg, A., Levi, M., Hack, C.E., Schoemaker, R.C., Cohen, A.F., Nuijens, J. J. Allergy Clin. Immunol. (2005) [Pubmed]
  25. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Ravindran, S., Grys, T.E., Welch, R.A., Schapira, M., Patston, P.A. Thromb. Haemost. (2004) [Pubmed]
  26. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. Han, E.D., MacFarlane, R.C., Mulligan, A.N., Scafidi, J., Davis, A.E. J. Clin. Invest. (2002) [Pubmed]
  27. AluY insertion (IVS4-52ins316alu) in the glycerol kinase gene from an individual with benign glycerol kinase deficiency. Zhang, Y., Dipple, K.M., Vilain, E., Huang, B.L., Finlayson, G., Therrell, B.L., Worley, K., Deininger, P., McCabe, E.R. Hum. Mutat. (2000) [Pubmed]
  28. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Sánchez Borges, M., Capriles-Hulett, A., Caballero-Fonseca, F., Pérez, C.R. Ann. Allergy Asthma Immunol. (2001) [Pubmed]
  29. Dermo-distortive urticaria: an autosomal dominant dermatologic disorder. Epstein, P.A., Kidd, K.K. Am. J. Med. Genet. (1981) [Pubmed]
  30. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. Gelfand, J.A., Sherins, R.J., Alling, D.W., Frank, M.M. N. Engl. J. Med. (1976) [Pubmed]
  31. Plasmapheresis in hereditary angioneurotic edema and systemic lupus erythematosus. Young, D.W., Thompson, R.A., Mackie, P.H. Arch. Intern. Med. (1980) [Pubmed]
  32. Intravenous heparin did not prevent exacerbations of hereditary angioedema in a patient on maintenance hemodialysis. Perricone, R., De Carolis, C., Fontana, L. J. Allergy Clin. Immunol. (2003) [Pubmed]
  33. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. Levi, M., Choi, G., Picavet, C., Hack, C.E. J. Allergy Clin. Immunol. (2006) [Pubmed]
  34. Exacerbation of a lupus-erythematosus-like syndrome during treatment of non-C1-esterase-inhibitor-dependent angioedema with danazol. Fretwell, M.D., Altman, L.C. J. Allergy Clin. Immunol. (1982) [Pubmed]
WikiGenes - Universities